Empirical Precision Medicine
Revolutionizing the way we treat cancer by providing empirical, personalized, drug response data prior to treatment selection in the clinic.
Recipient of September 2022 NIH/NCI R01 grant. See News for details.
Scroll down to learn more
Why this matters
Empirical drug sensitivity data will help healthcare providers make informed decisions, lower costs, and achieve better outcomes for patients.
At EMPIRI, our mission is to optimize cancer treatments within the boundary of reality yet unconstrained by prior knowledge. We strongly believe each patient’s tumor tissue is the best model for that patient. Our results are empirical determinations, not inferred predictions.
Our pragmatic and clinically validated approach is cancer agnostic and independent of genomic or histologic diagnosis.
A novel automated E-slice instrument, Cal™
Cal™ is a standalone instrument that automatically processes live, intact human tissues (biopsy cores or surgical material) and provides drug sensitivity results, both for short-term [days] or long-term [weeks] responses.
EMPIRI Cal™ is based on a proprietary 3D culture system using organotypic tumor slices (E-slices) that retain the integrity of each tumor's ecosystem. Our innovative and pragmatic approach measures cytotoxic effects of an individual drug or drug combinations with the goal of optimizing efficacy and minimizing toxicity for each cancer patient. This is the backbone of Cal™.
Services we provide
In parallel to our instrument development, EMPIRI provides cutting-edge correlative study services for clinical trials, using E-slice and single cell sequencing technologies.
We provide E-slice analysis using biopsy cores or surgical material to our select partners engaged in clinical trials in the TMC area. We can provide early response data in time to make agile decisions on your trial design and enrollment.
Single Cell Sequencing
We offer end-to-end single cell RNA sequencing service, from tissue dissociation to bioinformatics analysis. We decipher the complexity of each cancer ecosystem through droplet-based single cell RNA sequencing service, including immune profiling.